| Literature DB >> 3349002 |
Abstract
The effect of RU 486, a steroid acting as an antiprogestin at the receptor level, on uterine contractility and sensitivity to the prostaglandin analogue, 16-phenoxy-PGE2 methyl sulfonylamide (16-phenoxy-PGE2) and to oxytocin was studied in 29 women in early pregnancy. Seven untreated women at the same stage of pregnancy served as controls. In the untreated women no spontaneous uterine contractility was recorded and the response to 0.25 mg 16-phenoxy-PGE2 was characterized by an increase in uterine tonus with superimposed irregular contractions of low amplitude. Treatment with 25 mg RU 486 twice daily resulted in the appearance of regular uterine contractions at 24 h in two out of five patients and in all patients at 36, 48 and 72 h after the start of RU 486 treatment. The withdrawal of progesterone influence changed the inactive early pregnant uterus into an active organ. Administration of 16-phenoxy-PGE2 caused an obvious stimulation of both frequency and amplitude of the contractions. In addition, the significantly increased sensitivity to the prostaglandin analogue, but not to oxytocin, was already apparent 24 h after the start of RU 486 treatment. We have previously shown that the addition of one intramuscular injection of 16-phenoxy-PGE2 on the fourth day of treatment with RU 486 (25 mg twice daily) significantly increased the abortifacient effect of the antiprogestin during early pregnancy. The present study suggests that a shorter treatment may be possible.Entities:
Keywords: Abortion, Induced; Biology; Carboxylic Acids; Corpus Luteum Hormones; Demographic Factors; Developed Countries; Drugs--administraction and dosage; Endocrine System; Europe; Examinations And Diagnoses; Family Planning; Fertility Control, Postconception; Genital Effects, Female; Genitalia; Genitalia, Female; Hormone Receptors; Hormones; Ingredients And Chemicals; Laboratory Examinations And Diagnoses; Measurement; Membrane Proteins; Northern Europe; Organic Chemicals; Oxytocin--administraction and dosage; Physiology; Pituitary Hormones; Population; Population Characteristics; Pregnancy; Pregnancy, First Trimester; Progestational Hormones; Progesterone--analysis; Prostaglandins--administraction and dosage; Proteins; Reproduction; Reproductive Control Agents; Research Methodology; Scandinavia; Sweden; Treatment; Urogenital Effects; Urogenital System; Uterine Effects--analysis; Uterus
Mesh:
Substances:
Year: 1988 PMID: 3349002 DOI: 10.1111/j.1471-0528.1988.tb06840.x
Source DB: PubMed Journal: Br J Obstet Gynaecol ISSN: 0306-5456